ALBO

Albireo Pharma, Inc. [ALBO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALBO Stock Summary

In the News

ALBO Financial details

Company Rating
-
Market Cap
915.89M
Income
-137.38M
Revenue
57.39M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
130
Optionable
No
Shortable
Yes
Earnings
15 May 2023
P/E
-6.86
Forward P/E
-
PEG
12.47
P/S
36.83
P/B
8.67
P/C
-
P/FCF
-8.94
Quick Ratio
5.94
Current Ratio
6.32
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-7.04
EPS next Y
-
EPS next Q
-
EPS this Y
5.64%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
20.33%
Revenue last 5Y
734.95%
Revenue Q/Q
19.81%
EPS Q/Q
-10.55%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-39%
ROE
-105%
ROC
-0.39%
Gross Margin
93%
Oper. Margin
-448%
Profit Margin
-508%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.02-45.23
52W High
-
52W Low
-
RSI
-
Rel Volume
2.18
Avg Volume
566.9K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.03556
-
-
Volatility
0.05%, 0.05%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
AVGO
ABEA.DE
AAPL
JPM
VOO
Same Sector
0911.HK
HEXO
8513.HK
AMN
AEGIR.ST
Check Those
GLO.PA
MVEN
4928.T
BABP.JK
MI-UN.TO
Similar Market Cap
FGO.TO
TCL-A.TO
MCDHOLDING.NS
911608.TW
ORIENTLTD.NS

Company Profile

Healthcare Biotechnology
  • Volume Average 566.9K
  • Market Capitalization 915.89M
  • Employee 130
  • CEO Mr. Ronald H. W. Cooper
  • Headquarters Boston,MA,US
  • IPO Date 2007-05-11
  • Website https://www.albireopharma.com

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.